




SURVEILLANCE OF MAJOR BIRTH DEFECTS IN NON-LIVE BIRTH PREGNANCY OUTCOMES

EPIDEMIOLOGICAL CONSIDERATIONS

Glenda M. Ramirez, MPH
Epidemiologist
Arizona Birth Defects Monitoring Program
Arizona Department of Health Services

National Birth Defects Prevention Network

Surveillance Research Prevention



1

Objectives

- Provide overview for calculation of birth defect prevalence
- Discuss benefits of including non-live birth data for data analysis and epidemiological assessments
- Present some of the challenges of using non-live birth data
- Present potential ways to address the challenges with non-live birth data
- Discuss the gold standard vs. realistic alternatives

Acronyms:
BD – Birth defects
NBDPN – National Birth Defects Prevention Network
NTD – Neural Tube Defects

National Birth Defects Prevention Network

Surveillance Research Prevention

2

Overview of Calculation for Birth Defect Prevalence

- Case counts
- Prevalence estimates (overall & stratum-specific)
 - 95% confidence intervals
- Prevalence calculation
 - NBDPN recommendation:
$$\frac{\text{BD Cases}}{\text{All Live Births in Same Population}} \times 10,000$$

(Live Births + Fetal Deaths + Miscarriages + Terminations + Unknowns)

Anencephaly (Arizona, 2011-2015): $\frac{42+33}{427,550} \times 10,000 = 1.75 \text{ cases per } 10,000 \text{ live births}$

(Mason et al., 2005; NBDPN Guidelines, 2004)

National Birth Defects Prevention Network

Surveillance Research Prevention

3



Benefits of Including Non-Live Birth Data


- 1) More complete case ascertainment
 - Reduces risk of under-reporting that could occur with just live birth data
 - 1 BD case for every 33 pregnancies, yet 1 BD case for every 5 **stillborn** fetuses
 - Odds of **elective termination** are 126 times higher for fetuses with severe non-neurologic malformations
 - Odds of **elective termination** are 300 times higher for fetuses with serious neurologic malformations
 - Over 40% of pregnancies with neural tube defects were **electively terminated** after prenatal diagnosis (South Carolina, California)
 - Scant data in BD cases among **miscarriages**
 - Chromosomal abnormalities and NTDs

(Rynn, 2008; Hoyert, 2016; Gregory, 2013; Stillbirth Collaborative Research Network Writing Group 2011; Schechtman, 2002; Allen, 1996; Velic, 1996)

4

Benefits of Including Non-Live Birth Data

- 1) More complete case ascertainment
 - Miscarriages...



5

Benefits of Including Non-Live Birth Data

- 1) More complete case ascertainment
 - Arizona example
 - Anencephaly prevalence estimate, 2011-2015

$$\frac{\text{BD live birth cases}}{\text{All live births in Arizona}} \times 10,000 = \text{Prevalence Estimates} \quad \frac{42}{427,550} \times 10,000 = .98 \text{ cases per } 10,000 \text{ live births}$$

$$\frac{\text{BD live birth + BD fetal death cases}}{\text{All live births in Arizona}} \times 10,000 = \text{Prevalence Estimates} \quad \frac{42 + 33}{427,550} \times 10,000 = 1.75 \text{ cases per } 10,000 \text{ live births}$$

6



Benefits of Including Non-Live Birth Data

1) More complete case ascertainment

- Texas example
- Study in 2002

Defect	A. Cases ^a			B. Cases + terminations <20 weeks ^b			C. Terminations <20 weeks		D. % increase by including terminations ^c <20 weeks ^b
	No.	Rate ^d	95% CI ^e for rate	No.	Rate ^d	95% CI ^e for rate	No.	% of total defect occurrences ^b	
Imp	85	2.76	2.20-3.42	107	3.56	2.92-4.30	24	22.4	28.9
Ter	29	0.97	0.65-1.39	35	1.16	0.84-1.62	6	17.1	20.7
Ter	27	0.90	0.59-1.31	32	1.07	0.73-1.50	5	15.6	18.5
Ter	70	2.28	1.82-2.94	70	2.28	1.82-2.94	0	0.0	0.0
Ter	31	1.03	0.70-1.46	31	1.03	0.70-1.46	0	0.0	0.0
Ter	2	0.07	0.01-0.24	2	0.07	0.01-0.24	0	0.0	0.0
MAV	84	2.80	2.23-3.46	84	2.80	2.23-3.46	0	0.0	0.0
Ter	19	0.62	0.38-0.99	19	0.62	0.38-0.99	0	0.0	0.0
Ter	144	4.79	4.04-5.64	144	4.79	4.04-5.64	0	0.0	0.0

Background: The majority of U.S. birth defects surveillance programs do not include elective terminations weeks of gestation but exclude those at less than 20 weeks of gestation, while 15 programs (36%) include

Excluding non-live birth data can lead to an underestimation of prevalence estimates

(Ethen and Canfield, 2002)

7

Benefits of Including Non-Live Birth Data

2) More accurate evaluation of prevention efforts

- If non-live births are excluded, it can lead to underestimation of prevalence estimates and possible overestimation of success of prevention efforts.

3) Reduces potential bias in epidemiologic studies of birth defects

- If there are exposures and/or events of interest associated with the decision to terminate a pregnancy or a stillbirth, excluding non-live births could bias findings.

4) Assess & monitor terminations over time

- Cannot assume a consistent proportion of BD cases will result in terminations; thus, exclusion of elective terminations can underestimate prevalence.

(NBDPN Guidelines, 2012; Cragan and Khourey, 2000)

8

Some Challenges of Using Non-Live Birth Data

1) Classification/categories for non-live birth outcomes

- Not knowing, or being able to provide, accurate birth outcome (i.e. stillbirth vs miscarriage vs termination)

2) Inflation of prevalence estimates

- Certain BDs need a post-delivery confirmation or are poorly identified prenatally (e.g. certain congenital heart defects, chromosomal abnormalities)

3) Missing data for individual cases

- Race/ethnicity and sex are often missing
- Occurs most often for miscarriages and terminations in comparison to stillbirths

4) Missing BD cases among non-live births (incomplete ascertainment)

- Fetuses with certain BDs are more likely to undergo elective terminations early on, so may not have any record of the terminations

(NBDPN Guidelines, 2012)

9



THANK YOU!

Glenda M. Ramirez, MPH
Glenda.Ramirez@azdhs.gov
 Epidemiologist
 Arizona Birth Defects Monitoring Program
 Arizona Department of Health Services

National Birth Defects Prevention Network Surveillance Research **Prevention**

16

References

1. Mason, C. A., Kirby, R. S., Sever, L. E., & Langlois, P. H. (2005). Prevalence is the preferred measure of frequency of birth defects. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 73(10), 690–692. <https://doi.org/10.1002/bdra.20211>
2. NBDPN Guidelines for Conducting Birth Defects Surveillance Chapter 8 Statistical Methods. (2004). Retrieved February 6, 2020, from <http://www.nbdpn.org>
3. Rynn L, Cragan JD, Correa A. Update on overall prevalence of major birth defects—Atlanta, Georgia, 1978–2005. *MMWR Morb Mortal Wkly Rep* 2008;57:1–5.
4. Hoyert DL, Gregory EC. Cause of fetal death: data from the fetal death report, 2014. *Natl Vital Stat Rep* 2016;65:1–25.
5. Gregory ECW, MacDorman MF. Fetal and perinatal mortality: United States, 2013. *Natl Vital Stat Rep* 2015;64:1–24.
6. Stillbirth Collaborative Research Network Writing Group. Causes of death among stillbirths. *JAMA* 2011;306:2459–68.
7. Schechtman KB, Gray DL, Baty JD, Rothman SM. Decision-making for termination of pregnancies with fetal anomalies: analysis of 53,000 pregnancies. *Obstet Gynecol* 2002;99:216–22.
8. Allen WP, Stevenson RE, Thompson SJ, Dean JH. The impact of prenatal diagnosis on NTD surveillance. *Prenat Diagn.* 1996;16:531–535.

National Birth Defects Prevention Network Surveillance Research **Prevention**

17

References

9. Velie EM, Shaw GM. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991. *Am J Epidemiol.* 1996;144:473-479.
10. Miscarriages, Infertility, Birth Defects | Cornell Research. (n.d.). Retrieved February 10, 2020, from <https://research.cornell.edu/news-features/miscarriages-infertility-birth-defects>
11. Critical Periods of Development | MotherToBaby. (n.d.). Retrieved February 6, 2020, from <https://mothertobaby.org/factsheets/critical-periods-development/>
12. Ethen, M. K., & Canfield, M. A. (2002). Impact of including elective pregnancy terminations before 20 weeks gestation on birth defect rates. *Teratology*, 66(SUPPL. 1). <https://doi.org/10.1002/tera.90008>
13. NBDPN Guidelines for Conducting Birth Defects Surveillance Guidelines for Conducting Birth Defects Surveillance Inclusion of Prenatal Diagnoses in Birth Defects Surveillance. (2012). Retrieved February 6, 2020, from <http://www.nbdpn.org>
14. Cragan, J.D., Khoury, M.J., (2000). Effect of Prenatal Diagnosis on Epidemiologic Studies of Birth Defects. *Epidemiology*, 11(6), 695-699. DOI: 10.1097/0001648-200011000-00014
15. Massachusetts Department of Public Health (2019). Massachusetts Birth Defects 2013-2014. www.mass.gov/dph/birthdefects
16. Texas Birth Defects Epidemiology and Surveillance Report of Birth Defects Among 1999 - 2016 Deliveries. (n.d.). Retrieved February 6, 2020, from https://www.dshs.state.tx.us/birthdefects/data/BD_Data_99-16/Report-of-Birth-Defects-Among-1999-2016-Deliveries.aspx
17. Diagnosis of Birth Defects | CDC. (2004). Retrieved February 6, 2020, from <https://www.cdc.gov/nchs/did/birthdefects/diagnosis.html>

National Birth Defects Prevention Network Surveillance Research **Prevention**

18